Enhanced platelet aggregation responses to stimulation with ADP or thrombin receptor agonist peptides (TRAP) have been observed during heparin therapy in patients with unstable angina. However, the platelet aggregation curve in Figure 3 of the article by Xiao and Théroux 1 was not obtained from a direct detection to evaluate heparin-induced hyperaggregation.
sity of aggregates after heparin was significantly increased compared with that in nonresponders to heparin. Also, we obtained the same results by this system, that enhanced platelet aggregation response to heparin was not inhibited by aspirin or argatroban but was inhibited by anti-glycoprotein IIb/IIIa antibodies. The findings of enhanced platelet aggregation during heparin infusion in Figure 2 could be directly obtained without the addition of ADP or TRAP using the new device. In addition, the subjects in the article by Xiao and Théroux 1 could likely have been classified into 2 groups: responders and nonresponders to heparin. The authors would have obtained clearer conclusions regarding the effect of heparin on platelets in patients with unstable angina.
Direct detection of heparin-induced platelet aggregation may be a useful method to evaluate the efficacy of heparin therapy in coronary heart disease with enhanced platelet aggregation.
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